Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Comparison of Charlson comorbidity index scores of patients taking and not taking antiplatelet agents

From: Effect of continuation of antiplatelet therapy on survival in patients receiving physician home visits

ComorbidityTaking antiplatelets (n = 61)Not taking antiplatelets (n = 754)p valueTotal
(n = 815)
Acute myocardial infarction4 (6.6)7 (0.9)<  0.0111 (1.4)
Congestive heart failure14 (23.0)73 (9.7)<  0.0187 (10.7)
Peripheral vascular disease0 (0.0)2 (0.3)0.692 (0.3)
Cerebral infarction14 (23.0)33 (4.4)<  0.0147 (5.8)
Cerebral bleeding2 (3.3)13 (1.7)0.3915 (1.8)
Dementia5 (8.2)56 (7.4)0.8361 (7.5)
Pulmonary disease9 (14.8)55 (7.3)0.0464 (7.9)
Connective tissue disorder0 (0.0)0 (0.0)1.000 (0.0)
Peptic ulcer0 (0.0)5 (0.7)0.525 (0.6)
Mild to moderate liver disease0 (0.0)30 (4.0)0.1130 (3.7)
Diabetes12 (19.7)41 (5.4)<  0.0153 (6.5)
Paraplegia0 (0.0)1 (0.1)0.781 (0.1)
Renal disease5 (8.2)35 (4.6)0.2240 (4.9)
Diabetes with complications0 (0.0)2 (0.3)0.692 (0.3)
Cancer13 (21.3)321 (42.6)0.01334 (41.0)
Leukemia0 (0.0)2 (0.3)0.692 (0.2)
Malignant lymphoma0 (0.0)10 (1.3)0.3710 (1.2)
Severe liver disease0 (0.0)18 (2.4)0.2218 (2.2)
Metastatic cancer4 (6.6)74 (9.8)0.4178 (9.6)
HIV0 (0.0)0 (0.0)1.000 (0.0)
  1. Boldface indicates p value < 0.05